Assertio (ASRT) Holdings has reached a mutual agreement with Garda Therapeutics to postpone the commencement of the previously announced tender offer to acquire all outstanding shares of Assertio to May 8, 2026. As previously announced on May 4, 2026, Assertio has entered into an amended and restated merger agreement to be acquired by Garda for $21.80 per share in cash, or total cash consideration of $153.2M. The Company expects to file a Schedule 14D-9 in connection with the tender offer on May 8, 2026. In addition, Assertio will postpone the commencement of the previously announced tender offer for all outstanding Convertible Senior Notes until May 8, 2026.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASRT:
- Assertio price target raised to $21.80 from $18 at H.C. Wainwright
- Assertio Agrees to Enhanced All-Cash Acquisition by Garda
- Garda amends agreement to acquire Assertio to $21.80 per share in cash
- Assertio Extends Garda Tender Offer Commencement Deadline
- Assertio, Garda mutually agree to extend tender offer deadline